October 15, 2015
FDG-PET strongly predicts overall survival in patients suspected of having early-stage atypical Parkinsonian syndrome (APS), according to a study in the October Journal of Nuclear Medicine. The modality's findings closely matched clinical diagnosis at one-year follow-up.
In a comparison of patients with atypical Parkinsonian syndrome or similar forms of dementia, PET predicted a significantly shorter survival time of 4.1 years from the time of the initial PET scan for those with APS. Most interestingly, PET's prognostication matched survival time as determined by the clinical diagnosis at one year of follow-up.